학술논문
Phase II study of idelalisib, a selective inhibitor of PI3Kδ, for relapsed/refractory classical Hodgkin lymphoma
Document Type
Article
Author
Source
In Annals of Oncology May 2017 28(5):1057-1063
Subject
Language
ISSN
0923-7534